Mepolizumab is indicated for:

Add-on maintenance treatment of adults and children aged 6 years and older with severe asthma and an eosinophilic phenotype.
Add-on maintenance treatment of adults with chronic rhinosinusitis with nasal polyps (CRSwNP).
Add-on maintenance treatment of adults with chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype.
Treatment of adults with eosinophilic granulomatosis with polyangiitis (EGPA).
Treatment of adults and children aged 12 years and older with hypereosinophilic syndrome (HES) for at least 6 months without an identifiable non-hematologic secondary cause.

For blood cancers such as chronic eosinophilic leukemia, mepolizumab may be considered if the disease presents as a hypereosinophilic syndrome and other causes have been excluded.

mepolizumab

Common brand names

Approved use in